InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,388.65
(
0.83%
)
US TECH 100
18,299.80
(
1.35%
)
Dow Jones
39,450.86
(
0.24%
)
Brent Oil
80.77
(
-1.03%
)
Bitcoin
59,490.17
(
0.22%
)
Post# of 252865
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 835
Posts 120262
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Katsche post# 118470

Wednesday, 04/20/2011 4:39:01 AM

Wednesday, April 20, 2011 4:39:01 AM

Post# of 252865

I think the actual [Lovenox] run rate is $1.3B. The 247M in Q1 can split in 70M for Jan and Feb and 110M in March (script # jumps from 35000 (average) in Feb to 48000 in march and the new major GPO).

According to NVS’ CC, the March sales figure was boosted by initial stocking for two new GPO accounts. Hence, the annualized end-user run rate for generic Lovenox is clearly not as high as the $1.3B rate seen in March. Regards, Dew

p.s. Welcome back—you should post more often!

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up